Jiajian Robotics Secures Over RMB 100 Million in Series B Funding Led by Hillhouse Capital, Fosun Pharma, and BV Baidu Ventures; Files for IPO

VCBeat (WeChat ID: vcbeat) has learned exclusively that Jianjia Robot, an intelligent orthopedic surgical robot company, recently completed a Series B financing round of over RMB 100 million. The investment was jointly made by GL Ventures, Fosun Pharma, and existing shareholder Baidu Ventures, with HAOYUE CAPITAL continuing to serve as the exclusive financial advisor for this round. The funds raised will be used to advance the clinical registration of the company’s existing joint replacement surgical robots and to support the research and development of new products. In early 2020, Jianjia Robot completed a Series A financing round of tens of millions of RMB, with Baidu Ventures as the investor.

Regarding the consecutive investments from renowned institutions, Xu Jing, founder of Jianjia Robot, stated: “Currently, the success of joint replacement surgery heavily relies on surgeons’ experience and surgical skills. In this context, international orthopedic device giants such as Johnson & Johnson, Stryker, Zimmer Biomet, and Smith & Nephew have all entered the field of joint surgical robotics, signaling a clear industry trend. In the future, the application of joint surgical robots will become the sole breakthrough for improving the precision of prosthetic implantation and facilitating the scale-up of joint replacement surgeries. In this round of financing, Jianjia Robot is honored to partner with GL Ventures and Shanghai Fosun Pharmaceutical Investment Co., Ltd. We also extend our gratitude to our existing shareholder, Baidu Ventures, for its continued investment; to our angel investors, Puhua Capital and Kefa Capital, for their unwavering confidence; and to HAOYUE CAPITAL for its comprehensive support. With capital assistance, Jianjia Robot will accelerate the clinical trials and R&D of orthopedic surgical robots, striving to build a platform-based enterprise for surgical robotics and become a leading provider of comprehensive solutions and personalized diagnosis and treatment for orthopedic surgery in China.”

Founded in 2018, Jianjia Robot has rapidly emerged as a leading domestic enterprise in orthopedic surgical robotics, leveraging its core team’s extensive expertise in the integration of medicine and engineering, along with its independently developed surgical robot products protected by proprietary intellectual property rights. While pursuing independent innovation in key technologies, the Jianjia team closely aligns with clinical needs, effectively addressing the pain points associated with traditional manual joint replacement surgeries.

As the first domestically developed and independently innovated hip replacement surgical robot in China, Jianjia’s ARTHROBOT not only achieves precise positioning, reaming, and prosthesis implantation on the acetabular side but also covers femoral side processing. It controls the final surgical error within 1 mm and the implantation angle deviation within 1°, significantly addressing clinical pain points such as suboptimal precision in hip replacement surgeries, steep learning curves for surgeons, and long-term intraoperative radiation exposure. In the future, the application of surgical robots will, to a certain extent, drive progress across the entire field of joint surgery.

A representative from GL Ventures stated“Intelligent and precision treatment, represented by orthopedic surgical robots, is the future direction of orthopedic surgery. There is a strong clinical demand for joint surgery robots, as they can address the pain points of traditional joint replacement surgeries. Jianjia Robot possesses profound technological expertise, maintains close collaboration with clinical practices, and demonstrates strong team execution, positioning itself as a domestic leader in the field of hip replacement surgical robots. We look forward to working closely with the company and all investors over the long term to support its continuous innovation and rapid development, thereby creating greater value for China’s orthopedic industry.”

Project Lead, Jianjia, Fosun PharmaIt stated: “Substantial evidence indicates that minimally invasive joint replacement surgery significantly shortens patients’ hospital stays, rehabilitation periods, and time to return to society, thereby reducing healthcare costs. With the assistance of robotic systems for joint surgery, it is expected to overcome human-induced uncertainties associated with minimally invasive joint replacement and achieve consistent surgical outcomes. Jianjia Robot boasts an R&D team integrating medical and engineering expertise, with members possessing extensive experience in robot development. Less than three years after its establishment, the company’s first hip replacement surgical robot has entered clinical trials, marking a leading position in regulatory registration progress within the industry. Fosun Pharma’s wholly-owned subsidiary, USI (United States International, Inc.), formerly served as the exclusive distributor for the da Vinci Surgical System in China (including the Hong Kong and Macao Special Administrative Regions), accumulating rich marketing experience and industry resources in the field of medical robotics. Fosun Pharma will leverage USI to empower Jianjia Robot on the sales front, helping it rapidly expand its market presence and provide Chinese patients with high-precision, high-quality, and cost-effective joint replacement solutions.”

Head of Existing Shareholder Baidu Venturesstated: “As a new capability platform for enhancing the quality and efficiency of surgical procedures, intelligent surgical robot systems have demonstrated significant clinical potential and will further expand their capabilities with the rapid advancement of AI-driven perception, computing, and actuation technologies. Baidu Ventures (BV) has identified this sector as a core strategic focus, investing globally across the system’s industrial chain. This includes investments in various foundational technologies to establish an innovation platform for next-generation intelligent surgical robots, as well as backing outstanding product teams across clinical specialties to accelerate their growth. With the accelerating aging of the population, the orthopedic market is experiencing increasingly rapid growth, endowing orthopedic surgical robot systems with substantial market potential. In recent years, national policies have strongly encouraged and supported innovation in domestically produced medical devices. We believe the present moment offers an excellent opportunity for strategic investment. The Jianjia Robot project originated from the National 863 Program, with its core technical team hailing from the State Key Laboratory of Intelligence Technology and Systems at Tsinghua University and senior orthopedic clinical experts participating directly in frontline R&D. Its flagship joint robot product has entered the clinical trial phase. We are confident that Jianjia has the capability to become a world-class Chinese innovator and provider of intelligent surgical robotic solutions in the field of orthopedics, contributing to modern clinical surgery and delivering more precise, minimally invasive, and efficient surgical services to patients.”

Yang Zhenjun, Partner at HAOYUE CAPITALMr. Sheng stated, “Within just two years of its establishment, Jianjia Robot has progressed from R&D to the clinical trial stage for its first surgical robot product, positioning itself at the forefront of the industry. This achievement is underpinned by the team’s profound expertise in the field of surgical robotics, as well as their exceptional R&D and execution capabilities. HAOYUE CAPITAL is honored to have served as the exclusive financial advisor for Jianjia Robot’s Series A and B financing rounds. We believe that the company will accelerate the clinical trials, registration, and market launch of its orthopedic surgical robot products, thereby benefiting a broad patient population.”

GL Ventures is the venture capital fund under Hillhouse Capital that focuses on early-stage innovative companies. It primarily specializes in venture investments across four key sectors: biopharmaceuticals and medical devices, software services and original technological innovation, consumer internet and technology, and emerging consumer brands and services. Biopharmaceuticals and medical devices have long been a core investment focus for Hillhouse. Over the past decade, Hillhouse has invested in more than 160 outstanding pharmaceutical and medical device companies, including BeiGene, Innovent Biologics, Junshi Biosciences, I-Mab, Pharmaron, NanoMicro Technology, Medcaptain Medical Technology, PINS Medical, PriSMed, Peijia Medical, MicroPort CardioFlow, Venus Medtech, Easysurg Medical, Shenqi Medical, Biomime Medical, Antengene Corporation, Daming Group, Huamai Taikang, MicroPort CRM, Demede Medical, Beikang Medical, and Danxu Bio. We aim to partner with enterprises as “friends of time,” jointly promoting innovation and development in the broader healthcare sector to benefit more patients.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; Stock Codes: 600196.SH, 02196.HK), founded in 1994, is a leading healthcare industry group in China. With its business development rooted in China and strategically deployed globally, Fosun Pharma focuses on pharmaceutical manufacturing and R&D as its core, covering medical devices and diagnostics, healthcare services, and pharmaceutical distribution and retail. Looking to the future, under the guidance of its “4IN” strategy (Innovation, Internationalization, Integration, and Intelligentization) and adhering to its brand philosophy of “Continuous Innovation, Enjoyable Health,” Fosun Pharma is committed to becoming a first-class enterprise in mainstream global healthcare markets.

Baidu Ventures (BV) is an independent venture capital firm initiated by Baidu and managed by a professional team, with investors including Baidu and other leading industrial and financial institutions. BV currently manages three USD and RMB funds with a total scale of $500 million, operating simultaneously in Beijing and San Francisco, and is committed to becoming a world-class VC in the AI era.

HAOYUE CAPITAL was founded in January 2014, committed to becoming a bridge connecting China’s healthcare industry with capital. Its research and transaction coverage spans multiple sub-sectors, including biopharmaceuticals, innovative medical devices, IVD and precision medicine, healthcare services, and smart healthcare. The HAOYUE CAPITAL team comprises senior investment bankers with years of deep expertise in China’s healthcare sector. By closely tracking market dynamics and investment trends in healthcare over the long term, the firm releases weekly healthcare investment newsletters and thematic research reports, offering HAOYUE’s perspectives on new policies and emerging frontiers.